Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2026-01-26 Capital/Financing Update
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
전환가액의조정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (AdBiotech) detailing the adjustment of the conversion price for convertible bonds (CB). This type of disclosure, which involves changes to the capital structure and conversion terms of debt instruments, falls under the category of capital and financing updates. It is not a report publication announcement, but a direct disclosure of a corporate action regarding financing instruments.
2026-01-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document specifically details changes in share ownership by a major shareholder (Jung Hong-gul) in the company 'AdBiotech'. This falls under the category of Major Shareholding Notification (MRQ).
2026-01-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 6.1' report) used to disclose insider trading or changes in share ownership by company directors and major shareholders. This aligns perfectly with the 'Director's Dealing' (DIRS) category, which covers personal share transactions by company directors and executives.
2026-01-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically reporting a change in major shareholding status due to third-party capital increases and share transfers. This falls under the 'Major Shareholding Notification' category.
2026-01-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 95% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is used to disclose changes in share ownership by major shareholders or insiders. In the provided taxonomy, 'Major Shareholding Notification' (MRQ) is the correct category for notifications regarding changes in significant share ownership levels, including those by major shareholders.
2026-01-19 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for the company Adbiotech. It details the issuance of new shares, the purpose of the capital increase (operating funds), the third-party allocation details, and the impact on the company's share structure. This falls under the category of share issuance and capital changes.
2026-01-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.